Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for QSYMIA
- Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- Phase IV Study of Qsymia in Obese Patients
- A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subjects
- Comparing a Virtual vs. Face to Face Weight Management Program Using Phentermine for Patients With Overweight or Obesity
- Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker
- Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity
- A Phase IV Safety and Efficacy of VI-0521 in Obese Adolescents
- Individualized Obesity Pharmacotherapy
- Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)
- Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)
- EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
- FDA Approved Medication to Reduce Binge Eating and/or Purging
- Qsymia as an Adjunct to Surgical Therapy in the Superobese
- Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
- Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients
- A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)
Clinical trials list
click for details